Ubs Oconnor LLC Rezolute, Inc. Transaction History

Ubs Oconnor LLC

$1.51 Billion
Q4 2024

A detailed history of Ubs Oconnor LLC transactions in Rezolute, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 526,223 shares of RZLT stock, worth $2.47 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

526,223

Holding current value

$2.47 Million

% of portfolio

0.17%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.08 - $5.96 $354,919 - $518,460	86,990 Added 19.8%	526,223 $2.51 Million
Q3 2024 Nov 14, 2024	SELL	$4.13 - $5.31 $76,421 - $98,256	-18,504 Reduced 4.04%	439,233 $2.13 Million
Q2 2024 Aug 14, 2024	SELL	$2.29 - $5.79 $385,915 - $975,742	-168,522 Reduced 26.91%	457,737 $1.97 Million
Q1 2024 May 15, 2024	BUY	$0.95 - $2.55 $23,750 - $63,749	25,000 Added 4.16%	626,259 $1.6 Million
Q4 2023 Feb 14, 2024	BUY	$0.74 - $1.24 $32,524 - $54,500	43,952 Added 7.89%	601,259 $595,000
Q3 2023 Nov 14, 2023	BUY	$1.32 - $2.1 $112,200 - $178,500	85,000 Added 18.0%	557,307 $735,000
Q2 2023 Aug 14, 2023	BUY	$1.75 - $2.33 $826,537 - $1.1 Million	472,307 New	472,307 $935 Million
Q1 2023 May 15, 2023	BUY	$1.79 - $2.87 $770,550 - $1.24 Million	430,475 New	430,475 $826,000

Others Institutions Holding RZLT

# of Institutions

Shares Held

44.6M

Call Options Held

201K

Put Options Held

2.8K

Federated Hermes, Inc. Pittsburgh, PA

11.3M
Shares

$53 Million
0.13% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

2.86M
Shares

$13.4 Million
0.69% of portfolio
Vivo Capital, LLC Palo Alto, CA

2.8M
Shares

$13.1 Million
2.6% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.53M
Shares

$11.9 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

2.32M
Shares

$10.9 Million
0.0% of portfolio

View Full List

About Rezolute, Inc.

Ticker RZLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,600
Market Cap $182M
Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...

More about RZLT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account